Institutions / Catalio Capital Management, LP
Catalio Capital Management, LP
CIK 1958125 · Institution · as of Dec 31, 2025
Portfolio value
$565.79M
Positions
45
As of
Dec 31, 2025
Top holdings
Dec 31, 2025View all 45 →
| Company | Value | % of portfolio |
|---|---|---|
| Gilead Sciences, Inc. | $35.51M | 6.3% |
| Bristol Myers Squibb Co | $34.95M | 6.2% |
| Boston Scientific Corp | $34.37M | 6.1% |
| BridgeBio Oncology Therapeutics, Inc.BBOT | $31.41M | 5.6% |
| ELI LILLY & Co | $27.86M | 4.9% |
| Dianthus Therapeutics, Inc. | $26.93M | 4.8% |
| Ascendis Pharma A/S | $25.43M | 4.5% |
| Syndax Pharmaceuticals Inc | $25.14M | 4.4% |
| Johnson & Johnson | $25.01M | 4.4% |
| Regeneron Pharmaceuticals, Inc. | $23.00M | 4.1% |
| Structure Therapeutics Inc.GPCR | $17.59M | 3.1% |
| Soleno Therapeutics, Inc. | $16.68M | 2.9% |
| Cytokinetics Inc | $16.42M | 2.9% |
| Edwards Lifesciences Corp | $15.95M | 2.8% |
| Intuitive Surgical Inc | $15.41M | 2.7% |
| Natera, Inc. | $14.27M | 2.5% |
| Adaptive Biotechnologies Corp | $13.34M | 2.4% |
| Abivax SA | $13.29M | 2.3% |
| Supernus Pharmaceuticals Inc | $12.80M | 2.3% |
| Fractyl Health, Inc.GUTS | $12.08M | 2.1% |
| Mineralys Therapeutics IncMLYS | $12.04M | 2.1% |
| Phathom Pharmaceuticals, Inc.PHAT | $11.60M | 2.0% |
| ADMA Biologics Inc | $10.30M | 1.8% |
| Arcellx, Inc. | $10.18M | 1.8% |
| Dyne Therapeutics, Inc. | $10.17M | 1.8% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.